Replication-competent lentivirus analysis of clinical grade vector products

Kenneth Cornetta, Jing Yao, Aparna Jasti, Sue Koop, Makhaila Douglas, David Hsu, Larry A. Couture, Troy Hawkins, Lisa Duffy

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Lentiviral vectors are now in clinical trials for a variety of inherited and acquired disorders. A challenge for moving any viral vector into the clinic is the ability to screen the vector product for the presence of replication-competent virus. Assay development for replication-competent lentivirus (RCL) is particularly challenging because recombination of vector packaging plasmids and cellular DNA leading to RCL has not been reported with the current viral vector systems. Therefore, the genomic structure of a RCL remains theoretical. In this report, we describe a highly sensitive RCL assay suitable for screening vector product and have screened large-scale vector supernatant, cells used in vector production, and cells transduced with clinical grade vector. We discuss the limitations and challenges of the current assay, and suggest modifications that may improve the suitability of this assay for screening US Food and Drug Administration (US FDA)-licensed products.

Original languageEnglish
Pages (from-to)557-566
Number of pages10
JournalMolecular Therapy
Volume19
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Lentivirus
Product Packaging
United States Food and Drug Administration
Virus Replication
Genetic Recombination
Plasmids
Clinical Trials
DNA

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Cornetta, K., Yao, J., Jasti, A., Koop, S., Douglas, M., Hsu, D., ... Duffy, L. (2011). Replication-competent lentivirus analysis of clinical grade vector products. Molecular Therapy, 19(3), 557-566. https://doi.org/10.1038/mt.2010.278

Replication-competent lentivirus analysis of clinical grade vector products. / Cornetta, Kenneth; Yao, Jing; Jasti, Aparna; Koop, Sue; Douglas, Makhaila; Hsu, David; Couture, Larry A.; Hawkins, Troy; Duffy, Lisa.

In: Molecular Therapy, Vol. 19, No. 3, 03.2011, p. 557-566.

Research output: Contribution to journalArticle

Cornetta, K, Yao, J, Jasti, A, Koop, S, Douglas, M, Hsu, D, Couture, LA, Hawkins, T & Duffy, L 2011, 'Replication-competent lentivirus analysis of clinical grade vector products', Molecular Therapy, vol. 19, no. 3, pp. 557-566. https://doi.org/10.1038/mt.2010.278
Cornetta, Kenneth ; Yao, Jing ; Jasti, Aparna ; Koop, Sue ; Douglas, Makhaila ; Hsu, David ; Couture, Larry A. ; Hawkins, Troy ; Duffy, Lisa. / Replication-competent lentivirus analysis of clinical grade vector products. In: Molecular Therapy. 2011 ; Vol. 19, No. 3. pp. 557-566.
@article{139297b208f44036bfb831bc73d9ab97,
title = "Replication-competent lentivirus analysis of clinical grade vector products",
abstract = "Lentiviral vectors are now in clinical trials for a variety of inherited and acquired disorders. A challenge for moving any viral vector into the clinic is the ability to screen the vector product for the presence of replication-competent virus. Assay development for replication-competent lentivirus (RCL) is particularly challenging because recombination of vector packaging plasmids and cellular DNA leading to RCL has not been reported with the current viral vector systems. Therefore, the genomic structure of a RCL remains theoretical. In this report, we describe a highly sensitive RCL assay suitable for screening vector product and have screened large-scale vector supernatant, cells used in vector production, and cells transduced with clinical grade vector. We discuss the limitations and challenges of the current assay, and suggest modifications that may improve the suitability of this assay for screening US Food and Drug Administration (US FDA)-licensed products.",
author = "Kenneth Cornetta and Jing Yao and Aparna Jasti and Sue Koop and Makhaila Douglas and David Hsu and Couture, {Larry A.} and Troy Hawkins and Lisa Duffy",
year = "2011",
month = "3",
doi = "10.1038/mt.2010.278",
language = "English",
volume = "19",
pages = "557--566",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Replication-competent lentivirus analysis of clinical grade vector products

AU - Cornetta, Kenneth

AU - Yao, Jing

AU - Jasti, Aparna

AU - Koop, Sue

AU - Douglas, Makhaila

AU - Hsu, David

AU - Couture, Larry A.

AU - Hawkins, Troy

AU - Duffy, Lisa

PY - 2011/3

Y1 - 2011/3

N2 - Lentiviral vectors are now in clinical trials for a variety of inherited and acquired disorders. A challenge for moving any viral vector into the clinic is the ability to screen the vector product for the presence of replication-competent virus. Assay development for replication-competent lentivirus (RCL) is particularly challenging because recombination of vector packaging plasmids and cellular DNA leading to RCL has not been reported with the current viral vector systems. Therefore, the genomic structure of a RCL remains theoretical. In this report, we describe a highly sensitive RCL assay suitable for screening vector product and have screened large-scale vector supernatant, cells used in vector production, and cells transduced with clinical grade vector. We discuss the limitations and challenges of the current assay, and suggest modifications that may improve the suitability of this assay for screening US Food and Drug Administration (US FDA)-licensed products.

AB - Lentiviral vectors are now in clinical trials for a variety of inherited and acquired disorders. A challenge for moving any viral vector into the clinic is the ability to screen the vector product for the presence of replication-competent virus. Assay development for replication-competent lentivirus (RCL) is particularly challenging because recombination of vector packaging plasmids and cellular DNA leading to RCL has not been reported with the current viral vector systems. Therefore, the genomic structure of a RCL remains theoretical. In this report, we describe a highly sensitive RCL assay suitable for screening vector product and have screened large-scale vector supernatant, cells used in vector production, and cells transduced with clinical grade vector. We discuss the limitations and challenges of the current assay, and suggest modifications that may improve the suitability of this assay for screening US Food and Drug Administration (US FDA)-licensed products.

UR - http://www.scopus.com/inward/record.url?scp=79952183480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952183480&partnerID=8YFLogxK

U2 - 10.1038/mt.2010.278

DO - 10.1038/mt.2010.278

M3 - Article

VL - 19

SP - 557

EP - 566

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -